Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label expanded access study of lapatinib + capecitabine in HER2-positive advanced or metastatic breast cancer
2006-002080-93Phase 4Completed
- Sponsor
- GSK
- Start
- Aug 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lapatinib and capecitabine in breast cancer, sponsored by GSK. Primary endpoints: Progression-free survival and Overall survival. Started Aug 2006; status: completed.
02
Drugs
lapatinibcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-002080-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002080-93.